Pirtobrutinib/pirtobrutinib market price and official channel description in China

The overall market price of pitobrutinib in China is in a high range. The main reason is that the drug belongs to a new generation of BTK inhibitors, which has high research and development costs and has not yet been widely popularized. According to the available information, the specifications of the original research version currently sold in China are 100mg×14 tablets Although some hospitals and pharmacies can provide formal drug purchase channels, the specific price may still fluctuate slightly due to factors such as supply volume and channel differences. Patients are advised to refer to the public price of the hospital pharmacy or the channel approved by the State Food and Drug Administration.

In overseas markets, the price of pitubrutinib is higher, especially the version of the original drug sold in Europe and the United States. Common specifications include 50mg×30 tablets or 100 mg Differences in overseas sales prices mainly come from factors such as pricing systems, taxes, and insurance coverage in various countries. For patients who need to purchase drugs overseas, they also need to consider transportation, customs clearance and safety issues. Therefore, they must choose legal and qualified cross-border medical service institutions to avoid buying fake or illegal drugs.

It is worth noting that generic versions of Pitobrutinib (pirtobrutinib) have appeared overseas. The more common version comes from a Lao pharmaceutical factory. The specification is 50mg The chemical composition of generic drugs is basically the same as that of the original drugs, but there may still be differences in production standards, stability, dissolution and long-term clinical data. Although prices have been significantly reduced and accessibility has improved, patients must pay attention to the qualifications, legality and true ingredients of pharmaceutical companies when choosing generic drugs, and avoid buying products from unknown sources, inconsistent ingredients or insufficient efficacy.

Overall, the accessibility of pitubrutinib in China is gradually improving, but its price still poses a heavy burden to some patients. Current recommendations: If you are undergoing treatment in China, give priority to purchasing original drugs through formal hospital channels; if you are considering overseas versions or generic drugs, you should ensure that the channels are legal and reliable to avoid efficacy risks or safety hazards due to low prices.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC10841293/